Hormone therapyFDA-approvedSecond-line
Nubeqa
Generic name: darolutamide
How it works
Blocks the action of testosterone on cancer cells, slowing growth.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median overall survival of approximately 20 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Darolutamide with Surgery for High-Risk Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Comparing Darolutamide with Androgen Deprivation Therapy in Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Testosterone and Darolutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Studying Darolutamide Safety in Korean Men with Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Darolutamide's Benefit in Prostate Cancer Treatment | Prostate Cancer | phase-3 | In the Japanese subgroup, the probability that the darolutamide triplet provided greater utility was 0.601 when considering three criteria, and 0.975 when considering four criteria, including time to castration-resistant prostate cancer. | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| Darolutamide and Hormone Therapy for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], p = 0.03) compared with darolutamide + ADT. | Source → |
| Darolutamide Improves Prostate Cancer Treatment for Black Patients | Prostate Cancer | observational | Darolutamide + ADT resulted in an additional 1.04 (95% uncertainty interval 0.56-1.51) QALYs per treated patient relative to ADT, with the greatest gain observed among NH-Black patients (1.48 [0.48-2.71]). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.